⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 21, 2012Diabetes Obesity and MetabolismOpen Access

Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

Tim Heise Leszek Nosek Susanne Gammelgaard Bøttcher H. Hastrup Hanne Haahr

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

IDeg has a flat and consistent glucose-lowering effect in people with type 2 diabetes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Heise et al. (2012) studied this question.

synapsesocial.com/papers/69d7b5e30a5b166600f307b0 https://doi.org/10.1111/j.1463-1326.2012.01638.x

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesClinical Trial · 2007 · 240 citations
2Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.RCT · 2000 · 818 citations
3Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyOriginal Research · 2008 · 3,832 citations
4Insulin detemir under steady‐state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetesOriginal Research · 2006 · 38 citations
5Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 DiabetesRCT · 2004 · 617 citations

Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes2007
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes2012
Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes2006
Neuropsychiatric Outcomes Associated With GLP ‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity StatusDiabetes Obesity and Metabolism · 2026
Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time SeriesDiabetes Obesity and Metabolism · 2026

More from Diabetes Obesity and Metabolism